Close

Teva, Intel to develop wearable technology for Huntington's disease

Go back to Teva, Intel to develop wearable technology for Huntington's disease

Nomura Securities Raises Price Target on Intel (INTC) to $42

September 19, 2016 9:16 AM EDT

Nomura Securities reiterated a Buy rating on Intel (NASDAQ: INTC), and raised the price target to $42.00 (from $38.00). Intel raised its 3Q revenue expectations to $15.6b compared with its previous guidance of $14.9b, implying an EPS of $0.72 vs. Nomura's prior expectation of $0.66.

Analyst... More

UBS Raises Price Target on Intel (INTC) to $43 Ahead of 3Q Report

September 19, 2016 8:46 AM EDT

UBS reiterated a Buy rating on Intel (NASDAQ: INTC), and raised the price target to $43.00 (from $40.00), ahead of the company's 3Q earnings report. UBS believes that the company's stock will continue its positive momentum if Intel executes well in 3Q16 and reports y/y data center sales growth of 15%. Intel's new 3Q16 sales guidance is $15.6B versus its... More

Mizuho Securities Raises Price Target on Intel (INTC) to $42; Reiterates Buy

September 19, 2016 8:22 AM EDT

Mizuho Securities reiterated a Buy rating on Intel (NASDAQ: INTC), and raised the price target to $42.00 (from $38.00), following the company's September quarter preannouncement. INTC raised its midpoint of revenue expectations ~5%, from $14.9B to $15.6B due to PC inventory replenishment and better PC demand.

Analyst Vijay... More